{"id":109181,"plugin_id":"plugin_asdk_app_6a63bad25528819187bf1eeabd8a9af3","kind":"detail","collection_source":"plugin_api","comparison_source":"plugin_api","observed_at":"2026-11-21T06:10:21.857Z","digest":"6b43df2b88cf07c92b4d141e98ce8e3650c621519ab95c277d869a194767fd14","against":58451,"payload":{"canonical_app_id":"asdk_app_6a63bad25528819187bf1eeabd8a9af3","connector_id":"asdk_app_6a63bad25528819187bf1eeabd8a9af3","created_at":"2026-07-24T19:19:46.488012Z","discoverability":"LISTED","id":"plugin_asdk_app_6a63bad25528819187bf1eeabd8a9af3","is_template":false,"is_template_instance":false,"is_v2_template":false,"name":"app-6a63bad25528819187bf1eeabd8a9af3","release":{"app_ids":["asdk_app_6a63bad25528819187bf1eeabd8a9af3"],"app_manifest":{"apps":{"rhizome":{"id":"asdk_app_6a63bad25528819187bf1eeabd8a9af3","required":true}}},"app_templates":[],"description":"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com","display_name":"Rhizome AI","id":"pluginrel_4cd5b57bcf108191b0d849036869ea0e","interface":{"brand_color":null,"capabilities":[],"category":"Healthcare","composer_icon_dark_url":"https://files.openai.com/content?id=file_00000000ed70820eb61f8ad711b1b0f0","composer_icon_url":"https://files.openai.com/content?id=file_00000000e1c8820eb8d6431b0a223e87","default_prompt":"what do I need to do for an oncology IND for the FDA?","default_prompts":["what do I need to do for an oncology IND for the FDA?","what clinical trial sample sizes are typical for autoimmune rare disease therapies?","what are ideal predicates for full-body ultrasound scan that detects body comp and tries to find cancer?"],"developer_name":"Rhizome AI","logo_url":"https://files.openai.com/content?id=file_00000000960c820eb9bd23c8590d3574","logo_url_dark":"https://files.openai.com/content?id=file_00000000d078820ea9516dbe42442293","long_description":"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com","plugin_category_id":"healthcare","privacy_policy_url":"https://rhizomeai.com/privacypolicy","screenshot_urls":[],"short_description":"Cited FDA & EMA Answers","terms_of_service_url":"https://rhizomeai.com/termsofservice","website_url":"https://rhizomeai.com"},"keywords":[],"mcp_servers":[{"key":"rhizome","metadata":{"url":"https://rhizomeai.com/api/mcp"}}],"onboarding_skill_name":null,"requires_local_executor":false,"skills":[],"version":"3.2.0"},"scope":"GLOBAL","share_url":"https://chatgpt.com/plugins/rhizome-ai?open_in_app","status":"ENABLED"},"changes":[{"path":"/release/description","type":"changed","before":"Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks.\n\nWe're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. \n\nWe've indexed >3 TB worth of data put out by the FDA, EMA, MHRA, PMDA, etc., and built an agent that helps you:\n - automate precedents research \n - research FDA expectations around clinical endpoints, trial design, labeling, etc. \n - review briefing booklets, write pre-IND meeting packages, create white papers on almost any topic \n\nWhat you get:\n - each fact is backed by a citation, each citation is backed by the page of a health authority document \n - comprehensive answers that draw on up to 1,000 sources \n - we've had no hallucinations reported last 18 months \n\nFor more info, read rhizomeai.com/llms.txt\n\nFor support, reach out to support@rhizomeai.com","after":"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com"},{"path":"/release/id","type":"changed","before":"pluginrel_7aa3daeaaacc8191809b67f4f7310c7b","after":"pluginrel_4cd5b57bcf108191b0d849036869ea0e"},{"path":"/release/interface/composer_icon_dark_url","type":"changed","before":"https://files.openai.com/content?id=file_00000000da40820e9668db468514bdaa","after":"https://files.openai.com/content?id=file_00000000ed70820eb61f8ad711b1b0f0"},{"path":"/release/interface/composer_icon_url","type":"changed","before":"https://files.openai.com/content?id=file_00000000110c820ebf04c90a47aeb1af","after":"https://files.openai.com/content?id=file_00000000e1c8820eb8d6431b0a223e87"},{"path":"/release/interface/logo_url","type":"changed","before":"https://files.openai.com/content?id=file_000000009eb0820ea3100d5280f88cd6","after":"https://files.openai.com/content?id=file_00000000960c820eb9bd23c8590d3574"},{"path":"/release/interface/logo_url_dark","type":"changed","before":"https://files.openai.com/content?id=file_000000009a70820e8d51787e4db76793","after":"https://files.openai.com/content?id=file_00000000d078820ea9516dbe42442293"},{"path":"/release/interface/long_description","type":"changed","before":"Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks.\n\nWe're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. \n\nWe've indexed >3 TB worth of data put out by the FDA, EMA, MHRA, PMDA, etc., and built an agent that helps you:\n - automate precedents research \n - research FDA expectations around clinical endpoints, trial design, labeling, etc. \n - review briefing booklets, write pre-IND meeting packages, create white papers on almost any topic \n\nWhat you get:\n - each fact is backed by a citation, each citation is backed by the page of a health authority document \n - comprehensive answers that draw on up to 1,000 sources \n - we've had no hallucinations reported last 18 months \n\nFor more info, read rhizomeai.com/llms.txt\n\nFor support, reach out to support@rhizomeai.com","after":"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com"},{"path":"/release/interface/short_description","type":"changed","before":"Know what the FDA thinks","after":"Cited FDA & EMA Answers"},{"path":"/release/version","type":"changed","before":"3.1.0","after":"3.2.0"}],"summary":"Fields changed: 9. /release/description, /release/id, /release/interface/composer_icon_dark_url, /release/interface/composer_icon_url, /release/interface/logo_url, /release/interface/logo_url_dark, /release/interface/long_description, /release/interface/short_description ….","summary_kind":"deterministic","summary_metadata":{}}